ArticlePlastic and reconstructive surgery. Global open2020
Improvements in Skin Quality Biological Markers in Skin Explants Using Hyaluronic Acid Filler VYC-12L.
Article in Plastic and reconstructive surgery. Global open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06243744 (Histological Evaluation of Human Skin Biopsies to Assess the Effects of Renuvion APR Treatment as an Adjunct Procedure in Facelift Surgery), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Histological Evaluation of Human Skin Biopsies to Assess the Effects of Renuvion APR Treatment as an Adjunct Procedure in Facelift Surgery
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- A Prospective, Open-Label Study to Evaluate the Impact of VYC-12L Injection on Skin Quality Attributes in Healthy Volunteers.Clinical, cosmetic and investigational dermatology · 2022Trial
- VYC-17.5L is Safe and Effective in Improving Skin Quality and Volume Deficit of Hands: Results From an 18-Month Open-Label Study.Journal of cosmetic dermatology · 2026Article
- Round Table Discussion: Aesthetic Treatment Considerations for the Perimenopausal & Menopausal Patient.Journal of cosmetic dermatology · 2026Review
- Integrating VYC-12L With Energy-Based Devices for Skin-Quality Improvement: Global Expert Considerations for Safe and Effective Outcomes.Journal of cosmetic dermatology · 2025Article
- Skin Improvement in Japanese Patients With Inflammatory Dermatologic Conditions Using the Injectable Hyaluronic Acid VYC-12.Journal of cosmetic dermatology · 2025Article
- Dose-Dependent Effects of Cross-Linked Hyaluronic Acid Through Intradermal Injection on Female Facial Photoaging: A Prospective Study.Aesthetic surgery journal. Open forum · 2025Article
- Preparation and Rheological Evaluation of Thiol-Maleimide/Thiol-Thiol Double Self-Crosslinking Hyaluronic Acid-Based Hydrogels as Dermal Fillers for Aesthetic Medicine.Gels (Basel, Switzerland) · 2024Article
- Evaluation of Antioxidants' Ability to Enhance Hyaluronic-acid Based Topical Moisturizers.The Journal of clinical and aesthetic dermatology · 2024Article
- Potential of Biofermentative Unsulfated Chondroitin and Hyaluronic Acid in Dermal Repair.International journal of molecular sciences · 2022Article
- Treating Aging Changes of Facial Anatomical Layers with Hyaluronic Acid Fillers.Clinical, cosmetic and investigational dermatology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyaluronic acid (HA), both crosslinked and uncrosslinked, is used clinically to treat fine lines and provides additional improvements in skin quality attributes. The purpose of this study was to assess potential early differences in the expression of biological markers of skin quality in living human skin explants injected with uncrosslinked and crosslinked HA gels.
methodsLiving human skin explants injected with VYC-12L or noncrosslinked HA with mannitol (HYD) and noninjected controls were assessed via microscopy, histology, and immunohistochemistry on days 3 and/or 8 for biological markers of elasticity (collagen density, elastin, fibrillin-1) and hydration [aquaporin-3, acidic glycosaminoglycans (GAGs), HA]. Hydration was also assessed via a corneometer probe on days 0, 1, 2, and 8.
resultsOn day 3 versus controls, VYC-12L moderately increased collagen density in the upper reticular dermis and clearly increased fibrillin-1 expression, with slight increases persisting on day 8. Increases with HYD were smaller and did not persist on day 8. Both VYC-12L and HYD increased aquaporin-3 expression and GAG content on days 3 and 8, but VYC-12L produced greater GAG increases in the reticular dermis. Day 8 instrument-assessed hydration increased by 49% and 22% for VYC-12L and HYD, respectively. Elastin expression in oxytalan and elaunin fibers was unchanged. Upper-dermal HA reductions suggested HA injection-induced hyaluronidase expression.
conclusionVYC-12L produced greater, more lasting improvements in biological markers of skin quality than HYD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.